Humulin S (Soluble) (Insulin Human (Rdna))

Humulin S is indicated for the treatment of diabetes mellitus where insulin therapy is required.

• Type 1 diabetes mellitus (absolute insulin deficiency).
• Type 2 diabetes mellitus (insulin insufficiency or resistance).
• Management of hyperglycemia during pregnancy (gestational diabetes) when oral agents are unsuitable.
• Use in diabetic ketoacidosis as part of insulin replacement therapy.
• Adjunct to dietary control and exercise to achieve target glycemic levels.

• Humulin S contains recombinant human insulin that binds to insulin receptors on muscle, adipose and liver cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose concentrations. The overall effect is a rapid reduction in blood glucose levels after subcutaneous injection.

Like all insulin preparations, Humulin S may cause adverse reactions, ranging from mild to severe.

Common

• Hypoglycemia (low blood glucose).
• Injection‑site redness, swelling, or pain.
• Lipodystrophy at injection sites.
• Weight gain.
• Mild allergic skin rash.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Anaphylactic reaction.
• Hypokalemia.
• Edema or fluid retention.
• Development of insulin antibodies causing resistance.

Healthcare providers should consider several precautions when prescribing Humulin S to ensure safe and effective use.

• Regular monitoring of blood glucose and adjusting dose as needed.
• Dose adjustments may be required in renal or hepatic impairment.
• Caution in patients with hypoglycemia unawareness.
• Use only if benefits outweigh potential risks during pregnancy or lactation.
• Monitor serum potassium levels, especially if on diuretics.
• Educate patients on proper injection technique and site rotation.
• Assess cardiovascular status, as rapid glucose changes can affect heart function.

Humulin S can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Beta‑blockers (may mask hypoglycemia symptoms).
• Monoamine oxidase inhibitors (potentiate hypoglycemia).
• Oral hypoglycemic agents (additive glucose‑lowering effect).

Use with caution

• Corticosteroids (increase blood glucose, may require higher insulin dose).
• Thiazide diuretics (may raise glucose levels).
• ACE inhibitors (can enhance insulin sensitivity).
• Alcohol (risk of delayed hypoglycemia).